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Disorder of sex development (DSD) patients in Indonesia most often do not receive a proper diagnostic evaluation and treatment.
This study intended to categorize 88 Indonesian patients in accordance with the new consensus DSD algorithm. Diagnostic
evaluation including clinical, hormonal, genetic, imaging, surgical, and histological parameters was performed. Fifty-three patients
were raised asmales, and 34 as females. Of 22 patients with 46, XXDSD, 15 had congenital adrenal hyperplasia, while in one patient,
an ovarian Leydig cell tumor was found. In all 58 46, XY DSD patients, 29 were suspected of a disorder of androgen action (12 with
an androgen receptor mutation), and in 9, gonadal dysgenesis was found and, in 20, severe hypospadias e.c.i. Implementation of
the current consensus statement in a resource-poor environment is very difficult. The aim of the diagnostic workup in developing
countries should be to end up with an evidence-based diagnosis. This is essential to improve treatment and thereby to improve the
patients’ quality of life.
1. Introduction
The sequential expression of many genes is essential for go-
nadal development in the male as well as in the female [1, 2].
In addition, timely secretion and action of hormones such as
androgens and anti-Mu¨llerian hormone (AMH) are crucial
for normal male development [3]. Mutation analysis of genes
related to these factors in patients with genital disorders
has substantiated their essential role [4–7]. Therefore, in
a number of cases, a specific diagnosis can be made by
mutation analysis. Disorders of sex development (DSD) are
defined as congenital conditions in which development of
chromosomal, gonadal, or anatomical sex is atypical [8]. In
patients categorized under the term 46, XY or 46, XX DSD
with anomalies of gonadal development, often no specific
etiology can be established [9]. Yet the establishment of a
specific diagnosis is relevant with regard to proper gender
assignment as well as regarding hormonal and surgical
treatment. Moreover, patients with various forms of 46, XY
DSD and chromosomal DSD are at a substantially increased
risk of developing gonadal germ cell tumors [10].
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In Indonesia, patients presenting with DSD most often
do not receive a diagnostic evaluation and there are limited
options for medical and surgical treatment. In this study, we
performed a diagnostic evaluation in 88 patients with DSD
referred to a major Centre in Semarang, Indonesia. The aim
of this study was to categorize the patients in accordance with
the nomenclature proposed in the new consensus statement
[8]. Therefore, we performed a diagnostic evaluation includ-
ing clinical and hormonal parameters. Furthermore, results
from imaging and surgery as well as genetic and histological
parameters were evaluated.
2. Subject and Methods
2.1. Subjects. Eighty-eight patients (from 84 index patients)
with various forms and degrees of DSD were evaluated con-
secutively. They were referred for chromosomal analysis by
clinicians of the departments of Urology, Pediatrics, Internal
Medicine, and Obstetrics of the Dr. Kariadi Hospital,
Semarang, Indonesia. Referral took place between 2004
and 2006 to the department of Human Genetics Center
for Biomedical Research, Faculty of Medicine Diponegoro
University (FMDU), Semarang. Reason of referral was the
presence of ambiguous genitalia or any anatomical abnor-
mality of external or internal genitalia, including penoscrotal
hypospadias, with or without descended testes. Patients
with sex chromosome aberrations were included except
patients with classical Klinefelter (47, XXY) and Turner syn-
dromes (45, XO). In addition, four patients with cloacal
malformation were excluded.
All patients were recalled to the hospital for a physical
examination, pedigree construction, and collection of blood
for hormonal and gene mutation analyses. The age at initial
presentation was also the age of investigation and the start
of followup in 87 patients, and one patient with presumptive
CAH already received suppletion therapy for 9 months. The
local medical ethics committee approved this study, and in-
formed consent was obtained from all participants, their
parents, or guardians.
2.2. Methods. A stepwise diagnostic approach (Figure 1) was
used in order to determine the diagnosis in each patient.
First of all the patients were clinically evaluated, a detailed
description of the external genitalia was obtained, and the
genitalia were staged according to Quigley at al. [11]. The
assigned gender was also recorded. Subsequently, chromo-
somal patterns were determined, and, based on the results,
the patients were categorized according to the primary root
of the recent classification [8]: 46, XY DSD, 46, XX DSD,
or chromosomal DSD. In all patients, a blood sample was
obtained for hormonal and gene analysis; in patients with 46,
XY DSD, or Y containing chromosomal DSD, an additional
blood sample was obtained 72 hrs after the intramuscular
injection of 1500 IU hCG (Pregnyl Organon, Oss, The
Netherlands). The hCG test was not performed in 11 patients
for the following reasons: the gonads had been removed
(n = 3), logistic reasons (n = 7) and, in one patient, hCG
therapy had been started by the referring doctor in order to
enlarge the penis. Subsequently, imaging was offered to all
the patients as well as surgery in the form of a laparoscopy
or cystoscopy whenever needed for diagnostic options or
for gonadectomy in case of a high tumor risk. Based on
the results, a differential diagnosis was made followed by
gene mutation analysis. Finally, gonadal samples were ana-
lyzed when they were available in order to complete the
classification.
2.2.1. Chromosome Analysis. Karyotype was established us-
ing a G-banding technique in the Molecular and Cytoge-
netics Laboratory of the Center for Biomedical Research
of FMDU (Semarang). G banding was also performed for
confirmation of the presence of the Y chromosome.
2.2.2. Serum Hormones. Serum determinations of inhibin
B, AMH, LH, and FSH in the basal serum samples were
performed in the endocrine laboratory of Erasmus MC
(Rotterdam) as described previously [12]. Testosterone was
determined in serum collected before and after injection of
hCG using the Coat-a-Count radioimmunoassay purchased
from Siemens (Los Angeles, Calif) [12]. Androstenedione,
dehydroepiandrosterone sulphate, and progesterone were
also measured in these samples using the Immulite 2000
(Siemens). Finally, 17-hydroxyprogesterone levels were esti-
mated using an in-house method [13]. Reference values were
used as described earlier [12, 14].
2.2.3. Gene Analysis. DNA was extracted from leucocytes
of EDTA blood using the salting-out method as described
earlier [15]. Based on the clinical and hormonal information,
specific genes were analysed such as CYP21A2 [16], and LHR
[6]. AR, SRY, and WNT4 were analysed by direct sequence
analysis of the coding exons and exon-flanking intronic
regions (reference sequence AR [17, 18]: nm 000044.2 num-
bering according to Gottlieb et al. [18], SRY : X53772.1 and
WNT4: nm 030761.4).
2.2.4. Pathology. Histopathological assessments were per-
formed by means of hematoxylin and eosin stainings and
immunohistochemistry for various markers of germ cells,
for example, OCT3/4, TSPY, VASA, SCF (including double
staining for OCT3/4-TSPY or VASA); as well as SOX 9 and
FOXL2 for supportive cells [19].
3. Results
For a stepwise diagnostic approach, the algorithm shown in
Figure 1 was followed.
3.1. Clinical Evaluation and Chromosome Determination. All
88 patients were categorized according to their karyotype;
there were 22 patients with 46, XX DSD, 58 patients with 46,
XY DSD, and eight patients with chromosomal DSD.
Data on age, sex of rearing, and Quigley stage [11] of the
88 patients are provided in Table 1. The majority of patients
were older than two years at the time of referral; only six
patients were referred below the age of one year (Figure 2).
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Table 1: Phenotype (Quigley stage) in correlation with the DSD classification and sex of rearing. NA: not assigned, patient died after
inclusion but before gender assignment.
Classification
Consanguinity % Quigley stage Sex of rearing
1 2 3 4 5 6 Male Female NA
46, XX DSD 0 3 5 6 4 4 2 19 1
46 XY DSD 0 4 22 22 6 1 3 45 13
Chrom. DSD 0 1 3 0 2 0 2 5 3
Imaging Imaging ImagingSurgery
AMH/INHB AMH/INHB
Laparoscopy
MRI
HCG test MRI
Gonadal biopsy
Surgery
Laparoscopy
Gonadal biopsy
HCG test MRI
CAH Androgen excess MRKH XX-M Hypospadia Gon dysgen Gon dysgen
N = 15 N = 2 N = 4 N = 1 N = 29 N = 20 N = 9 N = 8
CYP 21 Androgen excess WNT4 SRY AR AR Gene mut SRY
100% 50% 0% 0% 41.4% 0% 0% 12.5%
88
DSD patients
Clinical evaluation
46 XX DSD
N = 22 (F 19, M 2, NA 1)
46 XY DSD
N = 58 (F 13, M 45)
Final classification
17-OH prog
Androstenedione
Chromosomal DSD
N = 8 (F 3, M 5)
Hormonal assessment
Hormonal
assessment
Hormonal
assessment
ultrasound ultrasound ultrasound
Androgen action
1
2
3
4
5
6
Gonadal histology
Figure 1: Stepwise diagnostic approach. An algorithm used with the aim of classifying the patients following the new classification system
[8]. Row number 1 represents the clinical evaluation of the patients and classification following the primary root; number 2 the hormonal
analysis and imaging followed by the secondary root classification (row 3). Row number 4 shows the percentage mutations that were found
and number 5 the gonadal histology leading to the tertiary root and final classification of the patients. Explanation of abbreviations: MRKH:
Mayer-Rokitansky-Ku¨stner-Hauser Syndrome; XX-M; XX male.
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Figure 2: Age distribution of the patients at presentation.
The group of 88 patients contains four families with two or
more patients with DSD (a total of nine). There was no
known consanguinity of the parents. Fifty-two patients were
raised as male and 35 as female,, while one patient’s gender
was undetermined due to early age; 16 patients (19%)
were raised discordant with their genotype (two males with
karyotype 46, XX and 14 females with karyotype 46, XY).
Two 46, XY patients changed gender from female into male
during the study, and one patient with a 46, XX karyotype
decided to live as a male. One patient with presumed an-
drogen excess died one week after inclusion without gender
assignment.
3.2. Hormonal Analysis, Imaging, and Surgery
3.2.1. 46, XX DSD. Hormonal analysis showed that out
of the 22 46, XX patients, 15 patients (68%) had serum
values of adrenal steroids suggesting CAH. Fourteen of
these 15 patients showed marked elevation of levels of 17-
hydroxyprogesterone, androstenedione, and testosterone. In
the remaining patient, these values were in the normal range
as she already received corticosteroid suppletion therapy
before referral. No patients with the salt wasting form of
CAH were found. As expected, AMH and inhibin B levels
were all in normal range for females (data not shown). In
one patient with no history of steroid medication, adrenal
steroid levels including cortisol were suggestive of cortisol
resistance. This could not be confirmed by sequencing the
glucocorticoid receptor gene, however.
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Extremely high testosterone levels (basal level of
59.9 nmol/L) and slightly increased values of gonadotropins
(LH: 12.3 IU/L, FSH: 8.1 IU/L) were identified in one 33-
year-old patient with Quigley stage 4, phallus length 2.5 cm,
and a low voice. Four patients had normal ovarian and
adrenal hormone levels and, in view of the clinical pre-
sentation, were suspected of having the Mayer-Rokitansky
syndrome [20].
One 11-year-old patient with the 46, XX male syndrome
with palpable gonads in the scrotum had normal FSH and
testosterone levels but low LH, AMH, and inhibin B levels
for boys of this age. Testosterone rose from 0.3 to 3.4 nmol/L
in response to hCG, suggesting that there were functional
Leydig cells.
Only in 12 of the 22 patients that were eligible, a diag-
nostic ultrasound was performed. In seven patients, surgery
was advised, and again only in two (28%) patients, diagnostic
surgery in the form of a laparoscopy or cystoscopy was done.
The remaining patients refused because of economic reasons.
3.2.2. 46, XY DSD. In all 58 patients, basal hormonal meas-
urements were obtained. LH levels were elevated in nine
patients, decreased in 35 patients, and normal for age in 14.
FSH levels were elevated in 18 patients and in the normal
range in the remaining 40. Finally, testosterone levels were
elevated in 15 patients, decreased in 36 patients, and normal
in seven patients.
Twelve patients showed elevated levels of AMH, 27 pa-
tients had levels in the normal range, and 17 patients had
decreased levels of AMH. In one patient, after gonadectomy,
AMH was not determined.
Inhibin B levels were elevated in 17 patients, normal
in 27 patients, and decreased in 14 patients. An hCG test
was performed in 47/58 patients (see methods), and 45 pa-
tients showed a sufficient response of testosterone and its
precursors. In two patients with a decreased response, Leydig
cell hypoplasia was suspected. Due to lack of material, we
could not test for DHT.
Diagnostic ultrasound was performed in 11 out of 58
(19%) patients, and, only in five (9%) patients, diagnostic
procedures in the form of a cystoscopy were performed. In
two (9%) of the 21 eligible patients, a gonadectomy was
performed. The remaining patients refused because of eco-
nomic and cultural reasons.
3.2.3. Chromosomal DSD. The karyotype of the eight pa-
tients is provided in Table 2. The basal level of LH was
increased for age in one patient. The level of FSH was
elevated in two patients (age 2 and 33 years) with low levels of
inhibin B in comparison with male values, while AMH and
inhibin B were increased in comparison to normal female
levels.
Ultrasound was performed in five out of eight (62.5%)
patients. In one (12.5%) patient a diagnostic procedure in the
form of a cystoscopy was done. In only one (12.5%) of the
eight eligible patients a gonadectomy was performed. The
remaining patients refused because of economic and cultural
Table 2: Karyotype of patients with chromosomal DSD.
Karyotype Number
XXY/XY 2
XY/X 2
XX/XXq- 2
XY/XX 1
XX/XXY 1
Total 8
reasons. Efforts to followup on these patients have been
performed.
3.3. Secondary Root Classification. Based on the hormonal
evaluation, imaging, and diagnostic surgery, the following
secondary root categorization was made.
3.3.1. 46, XX DSD. 15 patients were suspected of congenital
adrenal hyperplasia, one patient of a glucocorticoid receptor
defect, four patients with Mayer-Rokitansky Syndrome, one
patient with XX male syndrome, and one patient with
ovotesticular DSD.
3.3.2. 46, XY DSD. 29 patients were suspected of a disorder
of androgen action, nine with a disorder of gonadal develop-
ment, and 20 with severe hypospadias. We did not establish
the diagnosis testosterone synthesis disorders in any of the
patients, but we cannot rule out the presence of 5-alpha-
reductase deficiency in our patients without a definitive
diagnosis and a normal response of 5α-dihydrotestosterone
(DHT) levels to hCG.
3.3.3. Chromosomal DSD. All patients were categorized
under the second root diagnosis disorders of gonadal de-
velopment (gonadal dysgenesis).
3.4. Mutation Analysis. Based on these results, mutation
analysis was performed.
3.4.1. 46, XX DSD. Based on their phenotype, hormonal,
and chromosomal analysis,CYP21A2 analysis was performed
in 15 patients, and indeedCYP 21 genemutations were found
in all of them [16]. In four patients, clinically suspected of
having Mayer-Rokitansky syndrome, WNT4 gene analysis
was negative. One patient was suspected of a glucocorticoid
receptor defect; however, a mutation in the sequence of this
receptor was not found.
3.4.2. 46, XY DSD. Mutation analysis of the androgen
receptor (AR) gene was performed in 29 patients who were
suspected of having a disorder of androgen action and in 20
patients with severe hypospadias with a normal response to
hCG. In two index patients (four patients), pathogenic AR
mutations were found, R840H and 902insA. In an additional
two patients, the sequence variant V730M was found, of
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which it is unlikely that it is causing the phenotype; func-
tional studies showed that this variant is an activating muta-
tion. It has been described as a somatic variant in patients
with prostate cancer [21, 22]. In five index patients (six
patients), unclassified variants were found, I603N, 2170T>A;
P671S, 2373C>T; C175G, 885T>G; Q738R, 2575A>G; only
one of these four variants (C175G) has been described
at the nucleotide level. The three novel sequence variants
(I603N, P671S, and Q738R) were functionally investigated
[23]. Further mutation analysis for the SRD5A2 should be
performed for patients without AR gene mutation.
In the 20 patients with severe hypospadias, no AR mu-
tations were found.
Two patients suspected of having Leydig cell hypoplasia
were analyzed for a mutation in the LH receptor gene, but no
mutation was found.
3.4.3. Chromosomal DSD. An SRY deletion was found in one
patient with mosaic Klinefelter XX/XXY. In the remaining
seven patients, no SRY deletions were detected.
3.5. Gonadal Histology. Histology of the gonads was available
in four patients as shown in Table 3: one with 46, XX DSD
(biopsy as mentioned earlier), two with 46, XY and one with
chromosomal DSD (46, XY/46, XX).
One patient with 46, XX DSD had an ovarian Leydig
cell tumor. In this patient, ultrasonography did not reveal
abnormalities. However, a diagnostic laparoscopy showed
normal adrenal glands and large ovaries. During laparoscopy,
a biopsy was obtained. In a 23-year-old 46, XY patient, the
testis showed Leydig cell hyperplasia and atrophy of most
seminiferous tubules but no evidence of CIS. A thirteen-
year-old 46, XY boy was found to have Carcinoma in situ
(CIS), the precursor lesion for malignant germ cell tumors,
as reported recently [24]. Ovarian tissue with multiple cysts
including primordial follicles and granulosa cells was found
without evidence of malignancy in one patient with mosaic
XX/XY.
3.6. Final Classification. Based on the above-mentioned steps
in the diagnostic workup in patients with DSD syndromes, a
final classification was made following the current consensus
statement [8]. Data are shown in Table 4. In sixteen 46, XX
DSD patients (72%), a tertiary root classification was made,
in patients with 46, XY DSD, this was the case in 12 patients
(21%), and, in the group of patients with chromosomal
DSD, a tertiary root classification was made in one patient
(12.5%). Of course, the last category is a special one because
the chromosomal abnormalities itself are an explanation for
the etiology. In the remaining patients without an identified
genetic or pathologic cause of DSD, the tertiary root category
had to be “other.”
The 6 patients aged less than one year were diagnosed as
follows: androgen action disorder (2), excess androgen (2),
and unknown male undermasculinization (2).
The two 46, XY patients who changed gender from fe-
male to male had the final diagnosis of androgen action dis-
order, while one 46,XX CYP21A2-deficient patient decided
to live as a male.
4. Discussion
Reports on presentation and age distribution of DSD patients
in Asian countries are scarce and are mostly limited to CAH
patients [25–27]. The age of presentation of the DSD patients
in our study differs greatly from the age of presentation in the
western world. More than 75% of the patients were over two
years old. In India, 58% of the patients are referred within the
first year of life [26]. Reasons for this late clinical referral are
a lack of awareness among primary care providers, limited
diagnostic and therapeutic facilities, as well as socioeconomic
problems. Moreover, parents are reluctant to discuss sexual
issues, even with medical professionals [28]. Thailand has
started the multidisciplinary management of ambiguous
genitalia in 1979 [27], while, in Semarang, Indonesia, a start
was only made in 1999.
Out of 88 patients, nine (10.2%) were related, spread
over four families. There was no known consanguinity of the
parents in any of the cases. Thus, in only nine patients, a
familiar background suggestive of an inherited disease could
be established. One family with 2 affected children and their
cousin from mother’s side had the same AR gene mutations
(R840H). Identical mutations on CYP21A2 were found in 2
siblings in one family (IVS2-12A>G).
Based on physical examination, chromosomal analysis,
and hormonal data and in a limited set of patients imaging
and laparoscopy, the patients were categorized in accordance
with the current consensus statement [8]. A secondary root
diagnosis was made in all patients; however, it should be
noted that the secondary root includes male undermas-
culinization of unknown etiology, which was assigned in 20
patients (34%). However, we cannot rule out 5α-reductase
deficiency in these patients.
In 15 out of 22 patients with 46, XX DSD, the diagnosis
CAH based on CYP21A2mutations was made, including two
familial cases. As a result of the diagnostic procedure, 12
patients are presently under steroid treatment. Three patients
remained untreated (parents’ request): two of them are sibs,
and one of them showed a rather severe form of virilization.
This patient was raised as a male, and when the diagnosis of
CAH was made at the age of 17 yrs, he chose to continue to
live as a male after full explanation was given. The parents
decided to leave the 46, XX CAH sib (age 3 years) also
untreated and are raising this child as a male. Parents of
the third patient did not choose for hormonal treatment for
economic reasons. One patient with presumed CAH died
one week after inclusion. Because of lack of diagnostic and
treatment options, it is suspected that patients with 46, XX
DSD may have died from a crisis before coming to medical
attention due to salt loosing CAH [29, 30].
Interestingly, one patient at first thought to have CAH
turned out to have an androgen producing ovarian tumor
with the histology of Leydig cell tumor. This demonstrates
the value of histological examination of abdominal lesions in
these patients.
One patient was categorised as 46, XX, gonadal dysgene-
sis. Gene mutation analysis was done in a patient suspected
of a glucocorticoid receptor defect, but no mutant sequence
was found [31], and, in none of the four patients with the
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Table 4: Final classification.
DSD classification Number of patients Total
46, XX DSD
Disorder of androgen excess, other 2
Disorder of androgen excess, 21 hydroxylase deficiency 15
Defect of mullerian development, other 4
Disorder of gonadal development, ovotesticular DSD 1 22
46, XY DSD
Disorder of gonadal development, other 9
Disorder of androgen action, PAIS 12
Disorder of androgen action, other 17
Male undermasculinisation of unknown aetiology 20 58
Chromosomal DSD
46 XX/46 XY DSD, disorder of gonadal development,
ovotesticular DSD
1
47 XXY DSD, disorder of gonadal development, other 3
45X/46XY DSD, disorder of gonadal development, other 2
Other, disorder of gonadal development, other 2 8
clinical diagnosis of Mayer-Rokitansky Syndrome, a WNT4
mutation was detected [20].
Normal development and function of Sertoli cells and
Leydig cells are essential for hormone-mediated sex differ-
entiation of male internal and external genitalia.
In order to diagnose 46, XY DSD, determination of LH,
FSH, gonadal steroids, AMH, and inhibin B levels is essential.
Leydig cell activity is examined by hCG stimulation. In
our patients, measurement of testosterone precursors such
as androstenedione, 17-OH progesterone, progesterone, and
DHEA did not give evidence of a testosterone synthesis
disorder such as 17β-HSD or 17–20 lyase deficiency [5, 7].
Only in two patients, no rise of testosterone and its precur-
sors was observed after hCG stimulation, suggesting an LH
receptor defect. However, no mutation of the LH receptor
gene was found [32]. In most of the patients with the clinical
phenotype of Leydig cell hypoplasia, no causative mutations
are found [6].
In prepubertal patients, low AMH levels indicate mal-
functioning Sertoli cells in the testis. The best marker to
evaluate the presence of functional testis after puberty is
inhibin B [33]. Circulating concentrations of AMH remain
high until puberty when they fall in response to the effect
of testosterone. For this reason, we decided to categorize
normal AMH values based on testosterone levels [34].
We confirmed that increased AMH levels after puberty
(testosterone level >6 nmol/L) are suggestive for a disorder
of androgen action or synthesis. The combination of high
LH and testosterone levels in undermasculinized patients
also supports a defect in androgen action. However, in
only 12 (25%) of the in total 48 patients with 46, XY
DSD with clinical and hormonal features compatible with
altered androgen sensitivity, an AR mutation was found.
Two of the mutations were pathogenic, and four mutations
were unclassified variants which in later investigation were
found to be pathogenic [23]. All of these patients showed
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the typical features of partial androgen insensitivity. It is
noteworthy that 11 patients are being raised as males and
only one as female. In none of the patients classified as severe
(penoscrotal) hypospadias, an AR mutation was found.
All patients with chromosomal DSD had a chromosomal
mosaicism. Three patients had a Klinefelter variant; all of
them were raised as males.
Although imaging procedures are highly informative for
the establishment of a second root diagnosis, sonography was
only performed in 28/88 patients (31.8%) and a diagnostic
laparoscopy or cystoscopy was done in only nine of the
patients (10.2%). Limited facilities and economical problems
are the main reason for these relatively low numbers. In
30/58 patients with 46, XY DSD (51.7%), genital surgery was
performed such as hypospadias correction, gonadectomy,
and mastectomy. The rest of the patients (n = 28) remained
untreated mostly for economic reasons. Some patients or
parents refused the advice of the gender team and just
dropped out (n = 9). One assumption is that the cultural
reasons are of influence. Decision making is not just based
on what is recommended by the doctor but is influenced by
the family.
The risk of developing a malignant germ cell tumor is
increased in patients with DSD containing Y chromosomal
material, known as the gonadoblastoma locus on the Y chro-
mosome (GBY). This phenomenon is probably related to the
expression of the TSPY gene on the Y chromosome [19]. It
is important to mention that a nonscrotal position of the
gonad increases this risk. Proactive clinical interference, like
orchidopexy, biopsy, or even gonadectomy, is recommended
in patients with 46, XY DSD with maldevelopment of the
testes (with or without known gene mutation such as WT1)
and, in addition, in patients with PAIS, especially when the
gonads are in a nonpalpable position [10]. It is noteworthy
that, in our small sample of four gonadectomized patients,
already one patient with 46, XY DSD had developed carci-
noma in situ (CIS). This is the known precursor of malignant
germ cell tumors, which will progress to invasiveness in
about 70% within seven years. A biopsy was not performed
in all patients at risk because of the limited resources. This
raises the question whether a prophylactic gonadectomy in
all patients at risk for a malignancy should be performed.
At the moment, research is conducted focussing on the
identification of factors to estimate the actual cancer risk in
the individual patient to prevent unnecessary prophylactic
gonadectomy [10].
A point of debate is the inclusion of the histology and the
genetic analysis in a diagnostic workup. Of course mutation
analysis provides confirmation, whereas the histology is also
an important prognostic parameter as a base for further
treatment. We used the tertiary root only if a mutation was
found or if gonadal histology was known. This was the case
in 29 out of 88 patients (32%).
In conclusion, in daily practice the implementation of the
current consensus statement in a resource-poor environment
is very difficult. Especially the tertiary root classification that
is based on molecular genetic or histopathology diagnostics
is in many cases not feasible.
Therefore, we recommend the following stepwise ap-
proach: as a first step, a careful clinical evaluation, kary-
otyping of peripheral blood and sonographic imaging of the
internal genitalia should be performed in all patients.
Subsequently, in the 46 XX patients, rapid determination
of 17-hydroxyprogesterone in serum or saliva [35] is needed
in the first week of life in order to recognize a salt-loosing
CAH and prevent a life-threatening crisis. An increased level
is highly suggestive of the diagnosis CAH and needs to be
followed by immediate initiation of lifesaving treatment. In
patients with 46 XY or Y chromosome containing DSD,
determination of gonadotropins, testosterone, DHT, inhibin
B, and AMH is to be performed. Dependent on age and
stage of puberty, a second root working diagnosis can be
made allowing gender assignment and planning for further
diagnostic procedures and management in collaboration
with global DSD centers of excellence.
This implies the need for education of primary health
care workers on how to recognize DSD as a clinical fea-
ture that requires urgent assessment to prevent morbidity
and mortality in some cases. Protocols on referral pathways
should be implemented.
Unfortunately, in Indonesia, several factors such as
patients’ and general society’s opinion on DSD problems,
economic background of DSD patients, and lack of access to
health insurance can affect the complex management of DSD
in a negative way.
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